6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, OH
Reports First Quarter 2026 Results and Provides Pipeline Update
Annual Report to Security Holders
Announces Appointment of Keith A. Goldan to its Board of Directors
Abeona Therapeutics Inc. Adopts Third Amended and Restated Bylaws
Reports Full Year 2025 Financial Results and Corporate Updates
Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch
Reports Third Quarter 2025 Financial Results and Corporate Updates
Reports Second Quarter 2025 Financial Results and Corporate Updates
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership